Table 4.
Decrease in serum growth hormone concentrations [GH] from pretreatment values in patients who received different modalities of treatment.
| Treatment performed | ↓ [GH] ng/mL | ↓ [GH] % |
|---|---|---|
| Pretreatment GH(a) (n=21) | 25.6 (8.0 – 355.0) | – |
| After surgery (b) (n=21) | 14.5 (1.5 – 310.0) | 53.1 (12.7 – 83.0) |
| Surgery + RT (c) (n=9) | 8.10 (1.6 – 79.2) | 87.7 (14.0 – 96.8) |
| Surgery + RT + SRLs (d) (n=6) | 0.7 (0.3 – 8.7) | 98.7 (90.4 – 99.5) |
| Surgery + SRLs (e) (n=11) | 0.6 (0.2 – 7.9) | 95.2 (65.0 – 99.9) |
RT= radiotherapy; SRLs= somatostatin receptor ligands
Friedman's test followed by Dunn's test
a x b = p>0.05 (n=21)
a x b x c = p>0.05 (n=9)
a x b x c x d = p< 0.03; d < a, b, c (n=6); % values = d > a, b, c
Friedman's test followed by Dunn's test
a x b x e = p<0.05; e < b < a (n=11); % values = e > b
Mann-Whitney test
d x e = p>0.05; % values = p >0.05
c x e = p <0.05; e < c; % values = e > c.